Skip to Content Facebook Feature Image

Meritz Securities Connects to Bruce Markets' Data Feed for U.S. Equities, Improving Market Data for Korean Traders

Business

Meritz Securities Connects to Bruce Markets' Data Feed for U.S. Equities, Improving Market Data for Korean Traders
Business

Business

Meritz Securities Connects to Bruce Markets' Data Feed for U.S. Equities, Improving Market Data for Korean Traders

2026-09-14 07:30 Last Updated At:07:45

Demand for multi-venue competition grows in South Korea to prevent 'blind trading' during U.S. overnight session

CHICAGO and SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ -- Bruce Markets, which operates the overnight U.S. equities trading venue Bruce ATS, today announced that Meritz Securities, a leading Korean investment bank and broker-dealer, has connected to Bruce ATS' market data feed for overnight U.S. equities. The integration provides Meritz Securities with greater visibility into quote and trade activity on Bruce ATS throughout the 8:00 p.m. - 4:00 a.m. ET overnight U.S. session, broadening customers' view of U.S. equity prices during the Korean business day.

The milestone comes as South Korean traders fight 'blind trading' and reassert their role as one of the most important sources of overnight U.S. equity demand:

  • Korean brokerages resumed daytime access to U.S. stocks in November 2025 following a 15-month suspension, with stronger safeguards and a multi-venue framework.
  • Bruce Markets analysis found that total overnight notional activity nearly doubled between the November reopening and March 2026.
  • Since November 2025, several venue-specific symbol restrictions have reinforced the importance of multi-venue competition. Multiple trading venues help Korean retail traders access pricing data and avoid 'blind trading' – a need underscored in September when one venue halted trading in five symbols that collectively averaged 15+ million daily shares in August.

"Healthy markets are built on competition, transparency and choice. Bruce's share of reported overnight volume nearly doubled in Q2 because market participants increasingly recognize the value of having more than one credible source of liquidity and data," said Jason Wallach, CEO of Bruce Markets. "Meritz Securities' connection brings a more complete view of the overnight session in U.S. equities to one of its most important investor bases. That visibility is essential if Korean firms are going to prevent blind trading and deliver the high-quality experience customers deserve."

Meritz Securities' connection to Bruce ATS market data reflects accelerating growth in overnight U.S. equities. Across the three leading overnight ATSs, Q2 trading reached 11.14 billion shares and $391.2 billion in notional value – increases of 34% and 59% from Q1, respectively – according to the Bruce Q2 Overnight Market Review.

Bruce ATS accelerated significantly in Q2, with executed volume up 144% to 1.16 billion shares and executed notional up 105% to $49.03 billion. The momentum has continued into September, with Bruce's share of reported overnight notional climbing from 14.13% to a record 20.77%, and its share of monthly overnight volume rising from 11.66% to 16.4%.

"Meritz Securities is pleased to expand Korean investors' access to the U.S. overnight equity market through Bruce ATS," Meritz Securities said in a statement. "This collaboration reflects our commitment to providing clients with broader market access and a stable, reliable trading experience across extended trading hours."

As Korean demand for U.S. equities continues to expand, a competitive, multi-venue ecosystem ensures market resilience and gives brokers, traders and liquidity providers multiple pathways to see and reach liquidity across a wider range of market conditions.

About Bruce Markets
Bruce Markets operates Bruce ATS™, a U.S. equities alternative trading system enabling overnight trading from 8:00 PM to 4:00 AM ET. Underpinned by exchange-grade technology and market rules, led by industry veterans and backed by leading firms from across the trading ecosystem, Bruce provides a high-performance, resilient venue that bridges the U.S. after-hours and pre-market sessions. By providing a credible source of after-hours liquidity for brokers and investors and leading the evolution of always-available markets, Bruce brings needed competition to the ecosystem and is redefining after-hours trading worldwide. To learn more, visit www.brucemarkets.com.

About Meritz Securities
Meritz Securities Co., Ltd. is a South Korean financial services firm and member of Meritz Financial Group. The company provides securities brokerage, investment banking, sales and trading, and other financial services to retail, institutional and corporate clients. Meritz continues to expand its retail and global investing capabilities through technology-led platforms that bring together trading, information, analysis and investor communities. To learn more, visit home.imeritz.com.

Media Contacts
Forefront Communications for Bruce Markets
bruce@forefrontcomms.com 

Meritz Securities
prd@meritz.co.kr 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Meritz Securities Connects to Bruce Markets' Data Feed for U.S. Equities, Improving Market Data for Korean Traders

Meritz Securities Connects to Bruce Markets' Data Feed for U.S. Equities, Improving Market Data for Korean Traders

Certification supports European market access for a diagnostic test designed to aid the diagnosis of cervical precancerous lesions.

HOVIK, Norway, Nov. 19, 2026 /PRNewswire/ -- DNV, an EU Notified Body for the In Vitro Diagnostic Medical Devices Regulation (IVDR), has issued an IVDR certificate to FAMID Biomedical Technology (Tianjin) Co., Ltd for its diagnostic test designed to support the early detection of cervical cancer.

The certification was completed in just six months, following assessment of the manufacturer's quality management system, clinical evidence and technical documentation.

FAMID Biomedical's newly certified E7 Oncoprotein Rapid Test Kit, classified as a Class C in vitro diagnostic medical device under the IVDR, is designed as an aid in the diagnosis of cervical epithelial cell lesions through the detection of HPV E7 oncoprotein in cervical cell samples. The product is intended for both professional laboratory use and self-testing.

While every conformity assessment is different, the project demonstrates what can be achieved when a manufacturer enters the process well prepared.

Jim Miao, CEO of FAMID Biomedical Technology said:

"Bringing medical technologies to market requires not only strong technical capabilities, but also a certification partner who understands the importance of timely market access. Working with DNV has been a highly positive experience. Their professionalism, technical expertise and collaborative approach gave us confidence throughout the certification process and helped us progress efficiently towards bringing our technology to market. For our business, having a reliable and responsive partner is invaluable as we continue to develop our business and expand into new markets."

Cecilie Gudesen Torp, Managing Director of Medical Technologies, Life Sciences at DNV commented:

"Achieving IVDR certification just six months after contract signing is a significant achievement and reflects both FAMID Biomedical Technology's preparation and the expertise and close coordination of our teams throughout the assessment process. IVDR places significantly greater requirements on many diagnostic manufacturers, and this project demonstrates what can be achieved when strong preparation, specialist expertise and effective project management come together. Most importantly, the certification supports FAMID Biomedical Technology in bringing its diagnostic technology to the European market."

DNV has built specialist IVDR competence and capacity across its global Medical Technologies organisation to support manufacturers navigating these requirements and is working with a growing portfolio of IVD manufacturers globally, combining local customer engagement with specialist regulatory and technical expertise across its international organization.

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

DNV supports FAMID Biomedical Technology in achieving IVDR certification for its Class C IVD in six months

DNV supports FAMID Biomedical Technology in achieving IVDR certification for its Class C IVD in six months

DNV supports FAMID Biomedical Technology in achieving IVDR certification for its Class C IVD in six months

DNV supports FAMID Biomedical Technology in achieving IVDR certification for its Class C IVD in six months

Recommended Articles